The medtech company Regenlife is opening a new research centre at Biofortis (140 employees, €13 million turnover) in Nantes. This marks a further step “towards accelerating the recruitment of the 108 patients for the Light4life pivotal trial, aged between 55 and 85 and suffering from mild to moderate Alzheimer’s disease”, the company explains. Regenlife specialises in innovative photobiomodulation and neuromodulation technologies for the treatment of neurodegenerative diseases.